Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nihon Generic to Mount Aggressive Sales Campaigns Taking Advantage of Group Synergy
April 16, 2019
- Takeda Nabs Top Japanese Analyst for Global IR Team
April 16, 2019
- Mitsubishi Tanabe ALS Drug Accepted for Review in China
April 16, 2019
- Daiichi Sankyo’s Lyrica Contender Tarlige Now Available
April 16, 2019
- Bayer Japan Ethical Drug Sales Slip 1% in 2018
April 15, 2019
- AstraZeneca Japan on Track for 4 Launches in 2019, Dependence on Crestor Fades
April 15, 2019
- Amgen Looks to Debut 3 Oncology Drugs in Next 3 Years: Global Commercial Chief
April 12, 2019
- Sanofi, Yakult Close Down Zaltrap Copromotion
April 12, 2019
- Sumitomo Dainippon to Soon Decide What to Do with ADHD Med Dasotraline after Setback
April 12, 2019
- Sumitomo Dainippon Shoots for Sales of 600 Billion Yen in FY2022, Revving Up “Post-Latuda” Pipeline Acquisition
April 12, 2019
- Mitsubishi Tanabe Joins Shonan iPark; 1st Pharma Company without Financial Ties to Takeda
April 12, 2019
- Shionogi Licenses Constipation Med to BioDelivery Sciences for Commercialization in US
April 12, 2019
- Teva Takeda Plans to Roll Out One AG Annually: CEO
April 11, 2019
- Kyowa to Skip May Listing for Enbrel Biosimilar, Codeveloper YL Biologics to Move Ahead
April 11, 2019
- Nearly 300 Kyowa Kirin Staffers Offer to Leave under Redundancy Program
April 11, 2019
- Hisamitsu Sales Down 3.4% on Price Cuts, Generic Erosion
April 11, 2019
- Diabetes Drug Imeglimin Hits Primary Goal in Japan PIII: Sumitomo, Poxel
April 10, 2019
- Xofluza Most Promoted Drug in January: Anterio
April 10, 2019
- Drug Makers Scratching Heads to Meet Daily Rep Report Requirements for New Detailing Guidelines
April 10, 2019
- Medipal’s Subsidiary to Distribute Stemirac in Japan
April 9, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…